Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > RZLT Rezolute > Detailed Quotes

RZLT Rezolute

2.820
-0.130-4.41%
Close 09/23 16:00 ET
2.8200.0000.00%
Post Mkt Price 09/23 16:00 ET
High
3.000
Open
2.870
Turnover
72.44K
Low
2.655
Pre Close
2.950
Volume
25.07K
Market Cap
109.49M
P/E(TTM)
Loss
52wk High
8.560
Shares
38.83M
P/E(Static)
Loss
52wk Low
2.060
Float Cap
78.13M
Bid/Ask %
0.00%
Historical High
21.110
Shs Float
27.70M
Volume Ratio
0.56
Historical Low
2.060
Dividend TTM
--
Div Yield TTM
--
P/B
0.73
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.09%
Amplitude
11.70%
Avg Price
2.889
Lot Size
1
Float Cap
78.13M
Bid/Ask %
0.00%
Historical High
21.110
Shs Float
27.70M
Volume Ratio
0.56
Historical Low
2.060
Dividend TTM
--
P/B
0.73
Dividend LFY
--
Turnover Ratio
0.09%
Amplitude
11.70%
Avg Price
2.889
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperinsulinism, AB101-Phase 1, a once-weekly injectable basal insulin, and RZ402, which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.
CEO: Mr. Nevan C. Elam
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...